BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 23728524)

  • 1. The effect of mirabegron, a potent and selective β3-adrenoceptor agonist, on the pharmacokinetics of CYP2D6 substrates desipramine and metoprolol.
    Krauwinkel W; Dickinson J; Schaddelee M; Meijer J; Tretter R; van de Wetering J; Strabach G; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2014 Mar; 39(1):43-52. PubMed ID: 23728524
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
    Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
    Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
    Krauwinkel W; van Dijk J; Schaddelee M; Eltink C; Meijer J; Strabach G; van Marle S; Kerbusch V; van Gelderen M
    Clin Ther; 2012 Oct; 34(10):2144-60. PubMed ID: 23063375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single dose pharmacokinetics and absolute bioavailability of mirabegron, a β₃-adrenoceptor agonist for treatment of overactive bladder.
    Eltink C; Lee J; Schaddelee M; Zhang W; Kerbusch V; Meijer J; van Marle S; Grunenberg N; Kowalski D; Drogendijk T; Moy S; Iitsuka H; van Gelderen M; Matsushima H; Sawamoto T
    Int J Clin Pharmacol Ther; 2012 Nov; 50(11):838-50. PubMed ID: 22943933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
    Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
    Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
    Lin J; Goosen TC; Tse S; Yamagami H; Malhotra B
    J Clin Pharmacol; 2019 Nov; 59(11):1505-1518. PubMed ID: 31090092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of mirabegron, a β3-adrenoceptor agonist for treatment of overactive bladder, in healthy Japanese male subjects: results from single- and multiple-dose studies.
    Iitsuka H; Tokuno T; Amada Y; Matsushima H; Katashima M; Sawamoto T; Takusagawa S; van Gelderen M; Tanaka T; Miyahara H
    Clin Drug Investig; 2014 Jan; 34(1):27-35. PubMed ID: 24178236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Mirabegron, a β3-Adrenoceptor Agonist for Treatment of Overactive Bladder, in Healthy East Asian Subjects.
    Iitsuka H; van Gelderen M; Katashima M; Takusagawa S; Sawamoto T
    Clin Ther; 2015 May; 37(5):1031-44. PubMed ID: 25791612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
    Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
    Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase III Study to Assess Long-Term (52-Week) Safety and Efficacy of Mirabegron, a β
    Yamaguchi O; Ikeda Y; Ohkawa S
    Low Urin Tract Symptoms; 2017 Jan; 9(1):38-45. PubMed ID: 28120446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of CYP2D6 by quinidine and its effects on the metabolism of cilostazol.
    Bramer SL; Suri A
    Clin Pharmacokinet; 1999; 37 Suppl 2():41-51. PubMed ID: 10702886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic drug interaction study between overactive bladder drugs mirabegron and tolterodine in Japanese healthy postmenopausal females.
    Nomura Y; Iitsuka H; Toyoshima J; Kuroishi K; Hatta T; Kaibara A; Katashima M; Moy S; Sawamoto T
    Drug Metab Pharmacokinet; 2016 Dec; 31(6):411-416. PubMed ID: 27829538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety and efficacy of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A multicenter, randomized study in Japan (MILAI II study).
    Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K
    Int J Urol; 2019 Mar; 26(3):342-352. PubMed ID: 30548692
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers.
    Skinner MH; Kuan HY; Pan A; Sathirakul K; Knadler MP; Gonzales CR; Yeo KP; Reddy S; Lim M; Ayan-Oshodi M; Wise SD
    Clin Pharmacol Ther; 2003 Mar; 73(3):170-7. PubMed ID: 12621382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice.
    Chapple CR; Nazir J; Hakimi Z; Bowditch S; Fatoye F; Guelfucci F; Khemiri A; Siddiqui E; Wagg A
    Eur Urol; 2017 Sep; 72(3):389-399. PubMed ID: 28196724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study.
    Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2018 May; 10(2):122-130. PubMed ID: 27860325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mirabegron, a β₃-adrenoceptor agonist for the potential treatment of urinary frequency, urinary incontinence or urgency associated with overactive bladder.
    Tyagi P; Tyagi V
    IDrugs; 2010 Oct; 13(10):713-22. PubMed ID: 20878594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study.
    Yoshida M; Nozawa Y; Kato D; Tabuchi H; Kuroishi K
    Low Urin Tract Symptoms; 2019 Jan; 11(1):30-38. PubMed ID: 28901041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives.
    Groen-Wijnberg M; van Dijk J; Krauwinkel W; Kerbusch V; Meijer J; Tretter R; Zhang W; van Gelderen M
    Eur J Drug Metab Pharmacokinet; 2017 Jun; 42(3):417-429. PubMed ID: 27350625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.